Forum Discussion
CDK Inhibitors approved by PBAC 20 April 2018
CDK Inhibitors approved by the Pharmaceutical Benefits Advisory Committee (PBAC) but cost is still an issue. See the link below for further information https://www.bcna.org.au/news/2018/04/cdk-i...
Leapfrog,
You are ahead of me on this - I did not think there is an access program for Palbo - last I checked with Pfizer was couple of months ago... can you please share what do you know about this or can anyone/Giovanna add. Would be thrilled to know that is not correct.
My understanding is that Novartis offers a compassionate access programme for Ribociclib - I don't know the cost to the patient.
I am positive - Keytruda has gone through for lymphoma - immunotherapy trials do include it in some mets BC work - so the door is open on that too, I hope the government will not delay too much the CDKs.
You are ahead of me on this - I did not think there is an access program for Palbo - last I checked with Pfizer was couple of months ago... can you please share what do you know about this or can anyone/Giovanna add. Would be thrilled to know that is not correct.
My understanding is that Novartis offers a compassionate access programme for Ribociclib - I don't know the cost to the patient.
I am positive - Keytruda has gone through for lymphoma - immunotherapy trials do include it in some mets BC work - so the door is open on that too, I hope the government will not delay too much the CDKs.